Clinical trials: Acne Vulgaris
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Acne Vulgaris
Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris
This is a phase 2b, randomized, double-blind, vehicle-controlled clinical trial evaluating the efficacy, safety, and tolerability of B244 compared to vehicle in the treatment of moderate to severe acne vulgaris in adolescents and…
- Trial name
- NCT07866105
- Testing
- B244, Vehicle
- Volunteers
- 176 people
- Sponsor
- AOBiome LLC
Acne Vulgaris
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
- Trial name
- NCT02189629
- Testing
- CD5789 (trifarotene)
- Where
- 32 sites in United States, Czechia and 2 more
- Volunteers
- 453 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02566369
- Testing
- CD5789 (trifarotene) 50μg/g cream
- Where
- 124 sites in United States, Canada and 3 more
- Volunteers
- 1,208 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
- Trial name
- NCT02556788
- Testing
- CD5789 (trifarotene) 50µg/g Cream
- Where
- 81 sites in United States, Czechia and 6 more
- Volunteers
- 1,212 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris
This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.
- Trial name
- NCT02100527
- Testing
- PF-05175157
- Sponsor
- Pfizer
Acne
Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
- Trial name
- NCT01135069
- Testing
- Tretinoin microsphere 0.1%, Brand Retin-A Micro tretinoin microsphere gel 0.1%
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Spear Pharmaceuticals
Acne, Adult
Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health
The Embody retinol study is a single-arm clinical trial on skin aging prevention and adult acne. The purpose of this study is to determine the effect of a retinol gummy in adults aged 18-45 on skin aging and overall skin health.
- Trial name
- NCT04884516
- Testing
- Retinol gummy
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Embody Beauty, Inc.
Acne Vulgaris
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.
- Trial name
- NCT01498874
- Testing
- gevokizumab
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- XOMA (US) LLC
Acne Vulgaris
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel…
- Trial name
- NCT01769235
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Acanya® Gel, 1.2%/2.5%, Vehicle of test product
- Volunteers
- 1,215 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris
The purpose of this study is to explore the safety, tolerability, and preliminary efficacy of ALA used with photodynamic therapy for the treatment of moderate to severe acne vulgaris.
- Trial name
- NCT04018885
- Testing
- ALA 2.5%, ALA 5%, ALA 10%
- Where
- 4 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Acne Vulgaris
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in Subjects with acne vulgaris after a 12-week…
- Trial name
- NCT00441415
- Testing
- Adapalene BPO
- Where
- 4 sites in United States
- Volunteers
- 272 people
- Sponsor
- Galderma R&D
Scarring, Acne
Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece…
- Trial name
- NCT03430921
- Testing
- Enlighten™ Laser and a MLA Attachment
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Acne
A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation
This study will evaluate the efficacy of the Rael Miracle Clear Complete Acne Serum product in improving facial acne and post-acne pigmentation. This study will last for 56 days.
- Trial name
- NCT06120452
- Testing
- Rael Miracle Clear Complete Acne Serum
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Acne Vulgaris
Pharmacokinetics and Safety of ALA in Acne Vulgaris
This study will evaluate the pharmacokinetics and safety of ALA in patients with moderate and severe acne vulgaris after single dose in different dosages.
- Trial name
- NCT04044898
- Testing
- ALA 5%, ALA 10%
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815267
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 466 people
- Sponsor
- Vyne Therapeutics Inc.
Acne
Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.
- Trial name
- POWER (NCT01474590)
- Testing
- Epiduo/Tactuo, vehicle gel, doxycycline 200mg
- Where
- 25 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Study of a New Drug Treatment for Acne
A study to determine if three different doses of a new acne treatment are safe and better at reducing facial acne than a treatment without active ingredient.
- Trial name
- NCT01326780
- Testing
- 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA
- Where
- 18 sites in United States
- Volunteers
- 431 people
- Sponsor
- Bausch Health Americas, Inc.